TD Cowen analyst Tara Bancroft has maintained their bullish stance on MRUS stock, giving a Buy rating today.
Tara Bancroft’s rating is based on several promising developments in Merus’s clinical trials and regulatory progress. The Phase II data for the combination of petosemtamab (peto) and pembrolizumab (pembro) in first-line head and neck squamous cell carcinoma (1L HNSCC) showed a significant improvement in overall response rate compared to pembrolizumab alone, which is a strong indicator of the treatment’s potential efficacy. Additionally, the FDA’s granting of Breakthrough Therapy designation for this combination therapy, based on updated clinical data, underscores the potential for accelerated approval and is a positive signal for the company’s prospects.
Moreover, the ongoing Phase III trials, LiGeR-HN1 and LiGeR-HN2, are progressing well with enrollment metrics meeting or exceeding expectations. This smooth progression, coupled with the positive reception from the medical community following presentations at major conferences, suggests strong support for Merus’s clinical programs. These factors collectively contribute to the optimism surrounding Merus’s stock, justifying the Buy rating given by Tara Bancroft.
According to TipRanks, Bancroft is an analyst with an average return of -8.7% and a 22.83% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Merus, and Lantheus.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $100.00 price target.